XVIVO strengthens management team
XVIVO Perfusion’s management team is being strengthened in order to ensure a continued good development of the company. Karin Fischer, who assumes the position of Marketing and Sales Director Americas, and Pär-Ola Larsson, who assumes the position of Marketing and Sales Director EMEA, have been recruited externally. Emur Jensen, Director of Development, and Jenny Wennerberg, Director of Quality, have been employees at XVIVO Perfusion for three and two years, respectively.
As of January 1, 2016, XVIVO Perfusion’s management team will consist of six people, three of whom are stationed in the USA and three in Sweden. This will increase the company’s presence in the important American market. At the same time the company’s present global Marketing and Sales Director, Christer de Flon will go into retirement. He will take on the role of consultant with the task of developing the Asian market, which the company assesses will develop at an increasingly fast rate in the future.
Karin Fischer, Marketing and Sales Director for the Americas, has 15 years’ experience of the medical technology industry in several different clinical areas. Over the past 10 years she has held managerial positions in marketing and sales as well as quality at companies such as Johnson & Johnson and Getinge.
Pär-Ola Larsson, Marketing and Sales Director for EMEA, has many years’ experience of leading positions in the medical technology industry within sales, marketing and business development at companies such as Boston Scientific and Johnson & Johnson. He has been operative in the clinical areas of pulmonology, gastrology, thorax, sports medicines and neurovascular.
Emur Jensen, Director of Development, has almost 20 years’ experience of leading positions within the development and manufacturing of medical technology products. Over the past three years Emur has been responsible for development of the XPS™. He was previously plant manager at Vitrolife Inc. and before that he was responsible for technology- and process development at C & MI Inc.
Jenny Wennerberg, Director of Quality Assurance and Regulatory Affairs at XVIVO Perfusion since 2014. Previously QA/RA Manager at Integrum AB and before that 13 years´ experience with different Quality Assurance and R&D positions within medical device companies, such as Carmel Pharma.
“These additions to the management team will be an outstanding asset for us in the work of establishing EVLP with STEEN Solution™ and XPS™ as a standard treatment for lungs before transplantation. We warmly welcome Karin and Pär-Ola to XVIVO Perfusion as the roles of Marketing and Sales Director for the Americas and EMEA, respectively. We are pleased to have an extremely competent management team comprising such experienced co-workers,” says XVIVO Perfusion’s CEO, Magnus Nilsson.
December 8, 2015
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
The information was submitted for publication on December 8, 2015 at 8:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
Tags: